microRNA 4456 (MIR4456)

microRNA 4456 (MIR4456) is a short, non-coding RNA molecule involved in the post-transcriptional regulation of gene expression, primarily by binding to complementary sequences within target mRNAs to repress translation or promote mRNA decay[4][5]. In humans, MIR4456 has been found to have lower expression in individuals with hypersexual disorder, with its expression inversely associated with the methylation state of its associated CpG site (cg01299774); this site is also differentially methylated in alcohol dependence[1][3]. Pathway analyses have implicated MIR4456 in regulating genes preferentially expressed in the brain, notably in regions such as the amygdala and hippocampus, and its putative targets are enriched in neuronal signaling pathways, particularly the oxytocin signaling pathway[1]. MIR4456 is evolutionarily conserved across primates, but its gene is currently annotated only in humans[1]. At present, MIR4456 is not considered a classical therapeutic target (e.g., receptor, enzyme, transporter), nor are there known approved drugs that modulate its activity for clinical use. However, altered DNA methylation and expression patterns suggest it may have disease biomarker potential, principally in neuropsychiatric and substance use disorders[1][3].

Other names

hsa-mir-4456MIR4456hsa-miR-4456

Sequence-specific binding to mRNA targets resulting in inhibition of translation or promotion of mRNA degradation via the RNA interference pathway[4][5].